Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. August 2022 16:05 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
27. Juli 2022 16:05 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
25. Juli 2022 08:00 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
22. Juni 2022 08:00 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s Digital International Liver Congress™ 2022

-Similar significant reductions of hepatitis B virus (HBV) DNA and HBV RNA observed following 28 days of daily oral ALG-000184 dosing, regardless of HBeAg status, across first four dosing chronic...
06. Juni 2022 08:00 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
23. Mai 2022 16:05 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
04. Mai 2022 16:05 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
03. Mai 2022 08:00 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver’s International Liver Congress™ 2022

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address...
27. April 2022 16:05 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
04. April 2022 08:00 ET | Quelle: Aligos Therapeutics

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...

Vorherige Seite

Nächste Seite